Compare LAW & RNAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LAW | RNAC |
|---|---|---|
| Founded | 2013 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 220.0M | 238.9M |
| IPO Year | 2021 | 2016 |
| Metric | LAW | RNAC |
|---|---|---|
| Price | $4.15 | $8.11 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $8.00 | ★ $34.00 |
| AVG Volume (30 Days) | ★ 174.8K | 93.9K |
| Earning Date | 05-06-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 22.58 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $156,849,000.00 | $2,797,000.00 |
| Revenue This Year | $11.23 | N/A |
| Revenue Next Year | $10.60 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 8.29 | N/A |
| 52 Week Low | $2.45 | $5.60 |
| 52 Week High | $9.11 | $11.00 |
| Indicator | LAW | RNAC |
|---|---|---|
| Relative Strength Index (RSI) | 49.19 | 40.27 |
| Support Level | $4.00 | $5.88 |
| Resistance Level | $4.49 | $8.39 |
| Average True Range (ATR) | 0.15 | 0.50 |
| MACD | -0.01 | -0.16 |
| Stochastic Oscillator | 40.48 | 25.76 |
CS Disco Inc provides a cloud-native, artificial intelligence-powered legal solution that simplifies discovery, legal document review, and case management for enterprises, law firms, legal services providers, and governments. Its revenue-generating activities directly relate to the sale and support of legal solutions. It has two primary types of contractual arrangements: usage-based and subscription solutions. The usage-based revenue is derived from contracts under which customers are billed monthly based on their usage. Subscription revenue is derived from contracts where customers are contractually committed to a minimum data volume over a period of time.
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering cell therapy for the treatment of autoimmune diseases. The company uses technology and a manufacturing platform to introduce mRNA into cells to provide a therapeutic effect to patients suffering from a variety of autoimmune conditions. Unlike DNA, mRNA degrades naturally over time without integrating into the cell's genetic material.